Molecular pharmacology and pathophysiological significance of endothelin

Japanese Journal of Pharmacology

Volumn 72, Issue 4, 1996, Pages 261-290

  Goto, Katsutoshi ^a   Hama, Hiroshi ^a   Kasuya, Yoshitoshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Antagonist; Endothelin; Endothelin receptor; Pathophysiology; Signal transduction

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; BOSENTAN; BQ 610; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; IRL 2500; J 104121; L 754142; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; T 0115; TAK 044; TTA 386; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; AMINO TERMINAL SEQUENCE; BLOOD VESSEL WALL; BRAIN INJURY; BRAIN VASOSPASM; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL SECRETION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ANALYSIS; GENE EXPRESSION REGULATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MOLECULAR BIOLOGY; MOLECULAR CLONING; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE;

EID: 0030454012     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.72.261     Document Type: Review

References (285)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K and Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (1988)
2. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K and Masaki T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86, 2863-2867 (1989)
3. Takasaki C, Tamiya N, Bdolah A, Wollberg Z and Kochva E: Sarafotoxins S6: several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart. Toxicon 26, 543-548 (1988)
4. Sakurai T, Yanagisawa M, Inoue A, Ryan US, Kimura S, Mitsui Y, Goto K and Masaki T: cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem Biophys Res Commun 175, 44-47 (1991)
5. Sakurai T, Yanagisawa M and Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 13, 103-108 (1992)
6. Rubanyi GM and Polokoff MA: Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 46, 325-415 (1994)
7. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, Kamada N, Jishage K, Ouchi Y, Azuma S, Toyoda Y, Ishikawa T, Kumada M and Yazaki Y: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368, 703-710 (1994)
8. Hosoda K, Hammer RE, Giad A, Richardson JA, Baynash AG, Cheung JC, Giad A and Yanagisawa M: Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79, 1267-1276 (1994)
9. Puffenberger EG, Hosoda, K, Washington SS, Nakao K, deWit D, Yanagisawa M and Chakravarti A: A missense mutation of the endothelin-B-receptor gene in multigenic Hirschsprung's disease. Cell 79, 1257-1266 (1994)
10. Baynash AG, Hosoda K, Giaid A, Richardson JA, Emoto N, Hammer RE and Yanagisawa M: Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 79, 1277-1285 (1994)
11. Gronostajski RM: Site specific DNA binding of nuclear factor 1: effect of spacer region. Nucleic Acids Res 15, 5545-5559 (1987)
12. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M and Masaki T: The human preproendothelin-1 gene: Complete nucleotide sequence and regulation of expression. J Biol Chem 264, 14954-14959 (1989)
13. Emori T, Hirata Y, Imai T, Ohta K, Kanno K, Eguchi S and Marumo F: Cellular mechanisms of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. Biochem Pharmacol 44, 2409-2411 (1992)
14. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H and Yazaki Y: Transforming growth factor beta stimulates the expression of endothelin mRNA from vascular endothelial cells. Biochem Biophys Res Commun 159, 1435-1440 (1989)
15. Marsden PA and Brenner BM: Transcriptional regulation of the endothelin gene by TNF alpha. Am J Physiol 262, C854-C861 (1992)
16. Maemura K, Kurihara H, Morita T, Hayashi Y and Yazaki Y: Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontorogy 38, Supp 1, 29-35 (1992)
17. Marsden PA, Dorfman DM, Collins T, Brenner BM, Orkin SH and Ballermann BJ: Regulated expression of endothelin-1 in glomerular capillary endothelial cells. Am J Physiol 261, F117-F125 (1991)
18. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T and Marumo F: Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19, 753-757 (1992)
19. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, Imai T, Schichiri M and Marumo F: Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 18, 165-170 (1991)
20. Sharefki JB, Diamond SL, Eskin SG, McIntire LV and Fenbach CW: Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells. J Vasc Surg 14, 1-9 (1991)
21. Malek A and Izumo S: Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am J Physiol 263, C389-C396 (1992)
22. Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, Masaki T and Yazaki Y: Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 161, 859-864 (1989)
23. Sumpio BE and Widmann MD: Enhanced production of endothelium-derived contracting factor by endothelial cells subjected to pulsatile stretch. Surgery 108, 277-281 (1990)
24. Malek AM, Greene AL and Izumo S: Regulation of endothelin-1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci USA 90, 5999-6003 (1993)
25. Emori T, Hirata Y, Imai T, Eguchi S, Kanno K, Marumo F: Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 133, 2474-2480 (1993)
26. Imai T, Hirata Y, Emori T, Marumo F: Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension 21, 353-358 (1993)
27. Denault J-B, Claing A, D'Orleans-Juste P, Sawamura T, Kido T, Masaki T and Leduc R: Processing of proendothelin-1 by human furin convertase. FEBS Lett 362, 276-280 (1995)
28. Ohnaka K, Takayanagi R, Yamauchi T, Okazaki H, Ohashi M, Umeda F and Nawata H: Identification and characterization of endothelin converting activity in cultured bovine endothelial cells. Biochem Biophys Res Commun 168, 1128-1136 (1990)
29. Ikegawa R, Matsumura Y, Tsukahara Y, Takaoka M and Morimoto S: Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem Biophys Res Commun 171, 669-675 (1990)
30. Fukuroda T, Noguchi K, Tsuchida S, Nishikibe M, Ikemoto F, Okada K and Yano M: Inhibition of biological actions of big endothelin-1 by phosphoroamidon. Biochem Biophys Res Commun 172, 390-395 (1990)
31. Matsumura Y, Hisaki K, Takaoka M and Morimoto S: Phosphoramidon, a metalloprotase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol 185, 103-106 (1990)
32. Gardiner SM, Compton AM, Kemp PA and Bennett T: The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin (1-38) in conscious rats. Br J Pharmacol 103, 2009-2015 (1991)
33. Sawamura T, Kimura S, Shinmi O, Sugita Y, Yanagisawa M and Masaki T: Analysis of endothelin related peptides in culture supernatant of porcine aortic endothelial cells: Evidence for biosynthesis pathway of endothelin-1. Biochem Biophys Res Commun 162, 1287-1294 (1989)
34. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D and Yanagisawa M: ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78, 473-485 (1994)
35. Shimada K, Takahashi M and Tanzawa K: Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 269, 18275-18278 (1994)
36. Ikura T, Sawamura T, Shiraki T, Hosokawa H, Kido T, Hoshikawa H, Shimada K, Tanzawa K, Kobayashi S, Miwa S and Masaki T: cDNA cloning and expression of bovine endothelin converting enzyme. Biochem Biophys Res Commun 203, 1417-1422 (1994)
37. Emoto N and Yanagisawa M: Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 279, 16262-16268 (1995)
38. 22]-Big endothelin-1[19-17]: a new and potent inhibitor of the endothelin-converting enzyme. J Cardiovasc Pharmacol 26, Supp 3, S72-S74 (1995)
39. Shiba R, Yanagisawa M, Miyauchi T, Ishii Y, Kimura S, Uchiyama Y, Masaki T and Goto K: Elimination of intravenously injected endothelin-1 from the circulation of the rat. J Cardiovasc Pharmacol 13, Supp 5, S98-S101 (1989)
40. Anggard E, Galton S, Rae G, Thomas R, McLoughlin L, De Nucci G and Vane JR: The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol 13, Supp 5, S46-S49 (1989)
41. Advenier C, Sarria B, Naline E, Puybasset L and Lagente V: Contractile activity of three endothelins (ET 1, ET 2 and ET 3) on the human isolated bronchus. Br J Pharmacol 100, 168-172 (1990)
42. Maggi CA, Giuliani S, Patacchini R, Barbanti O, Turini D and Meli A: Contractile responses of the human urinary bladder, renal pelvis and renal artery to endothelins and sarafotoxin S6b. Gen Pharmacol 21, 247-249 (1990)
43. Bousso-Mittler D, Galton R and Sokolovsky M. Endothelin/sarafotoxin receptor heterogeneity: evidence for different glycosylation in receptors from different tissues. Biochem Biophys Res Commun 178, 921-926 (1991)
44. Galron R, Kloog Y, Bdolah A and Sokolovsky M: Different pathways of endothelin/sarafotoxin stimulated phosphoinositide hydrolysis in myosites. Eur J Pharmacol 188, 85-88 (1990)
45. Gomez-Sanchez CE, Cozza EN, Foeching MF, Chiou S and Ferris MW: Endothelin receptor subtypes and stimulation of aldosterone secretion. Hypertension 15, 744-747 (1990)
46. Martin ER, Brenner BM and Ballermann BJ: Heterogeneity of cell surface endothelin receptors. J Biol Chem 265, 14044-14049 (1990)
47. Ohnishi-Suzaki A, Yamaguchi K, Kusuhara M, Adachi I, Abe K and Kimura S: Comparison of biological activities of endothelin-1, -2 and -3 in murine and human fibroblast cell lines. Biochem Biophys Res Commun 166, 608-614 (1990)
48. Takuwa Y, Masaki T and Yamashita K: The effects of the endothelin family on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 170, 998-1005 (1990)
49. Warner TD, Mitchell JA, De Nucci G and Vane JR: Endothelin 1 and endothelin 3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 13, Supp 5, S85-S88 (1989)
50. Wallace JL, Keenan CM, McNaughton WK and McKnight GW: Comparison of the effects of endothelin 1 and endothelin 3 on the rat stomach. Eur J Pharmacol 167, 41-47 (1989)
51. Lidbury PS, Thiemermann C, Thomas GR and Vane JR: Endothelin-3: selectivity as an anti-aggregatory peptide in vivo. Eur J Pharmacol 166, 335-338 (1989)
52. Crawford ML, Hiley CR and Young JM: Characteristics of endothelin 1 and endothelin 3 stimulation of phosphoinositide breakdown differ between regions of guinea pig and rat brain. Naunyn Schmiedebergs Arch Pharmacol 341, 268-271 (1990)
53. Marsault R, Vigne P, Breittmayer JP and Frelin C: Astrocytes are target cells for endothelin and sarafotoxin. J Neurochem 54, 2142-2144 (1990)
54. Galron R, Bdolah A, Kochva E, Wollberg Z, Kloog Y and Sokolovsky M: Kinetic and cross linking studies indicate different receptors for endothelins and sarafotoxins in the ileum and cerebellum. FEBS Lett 283, 11-14 (1991)
55. Watanabe H, Miyazaki H, Kondoh M, Masuda Y, Kimura S, Yanagisawa M, Masaki T and Murakami K: Two distinct types of endothelin receptors are present on chick cardiac membranes. Biochem Biophys Res Commun 161, 1252-1259 (1989)
56. Masuda Y: Two different forms of endothelin receptors in rat lung. FEBS Lett 257, 208-210 (1989)
57. Sugiura M, Snajdar RM, Schwartzberg M, Badr KF and Inagami T: Identification of two types of specific endothelin receptors in rat mesangial cell. Biochem Biophys Res Commun 162, 1396-1401 (1989)
58. Nakajo S, Sugiura M, Inagami T, Nitta K, Naruse M, Sanaka T, Tsuchiya K, Naruse K, Zeng ZP, Demura H and Sugino N: Native form of endothelin receptor in human placental membrane. Biochem Biophys Res Commun 167, 280-286 (1990)
59. Schvartz I, Ittoop O and Hazum E: Bovine cerebellum endothelin receptor: solubilization and identification. Endocrinology 126, 3218-3222 (1990)
60. Arai H, Hori S, Aramori I, Aramori I, Ohkub H and Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348, 730-732 (1990)
61. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K and Masaki T: Cloning of a cDNA encoding a non isopeptide selective subtype of the endothelin receptor. Nature 348, 732-735 (1990)
62. Lin HY, Kaji EH, Winkel GK, Ives HE and Lodish HF: Cloning and functional expression of a vascular smooth muscle endothelin receptor. Proc Natl Acad Sci USA 88, 3185-3189 (1991)
63. Elshourbagy NA, Lee JA, Korman DR, Nuthalaganti P, Sylvester DR, Dilella AG, Sutiphong JA and Kumar CS: Molecular cloning of the major endothelin receptor subtype in porcine cerebellum. Mol Pharmacol 41, 465-473 (1992)
64. Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, Nakanishi S and Imura H: Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin A receptor. J Biol Chem 267, 18797-18804 (1992)
65. B endothelin receptor. Biochem Biophys Res Commun 178, 656-663 (1991)
66. B-like receptors. Biochem Biophys Res Commun 184, 100-106 (1992)
67. B receptors mediate vascular smooth muscle contraction. Br J Pharmacol 107, 858-860 (1992)
68. Sujarwo SA, Hori M, Takai M, Urade Y, Okada T and Karaki H: A novel subtype of endothelin B receptor mediating contraction in swine pulmonary vein. Life Sci 53, 431-437 (1993)
69. Emori T, Hirata Y and Marumo F: Specific receptors for endothelin 3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett 263, 261-264 (1990)
70. Samson WK, Skala K, Huang FL, Gluntz S, Alexander B and Gomez Sanchez CE: Central nervous system action of endothelin 3 to inhibit water drinking in the rat. Brain Res 539, 347-351 (1991)
71. B receptors mediating venous smooth muscle contraction. Biochem Biophys Res Commun 200, 627-633 (1994)
72. Riezebos J, Watts IS and Vallance PJY: Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol 111, 609-615 (1994)
73. C receptor) from Xenopus laevis dermal melanophores. J Biol Chem 268, 19126-19133 (1993)
74. Kumar C, Mwangi V, Nuthulaganti P, Wu HL, Pullen M, Brun K, Aiyar H, Morris RA, Naughton R and Nambi P: Cloning and characterization of a novel endothelin receptor from Xenopus heart. J Biol Chem 269, 13414-13420 (1994)
75. Hirata Y, Yoshimi H, Takaichi S, Yanagisawa M and Masaki T: Binding and receptor down regulation of a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Lett 239, 13-17 (1988)
76. Devesly P, Phillips PE, Johns A, Rubanyi GM and Parker-Botelho LH: Receptor kinetics differ for endothelin 1 and endothelin 2 binding to Swiss 3T3 fibroblasts. Biochem Biophys Res Commun 172, 126-134 (1990)
77. Thomas CP, Baldi E, Simonson MS, Kester M and Dunn MJ: Endothelin receptors and coupled GTP binding proteins in glomerular mesangial cells. J Cardiovasc Pharmacol 17, Supp 7, S79-S84 (1991)
78. Resink TJ, Scott-Burden T and Buhler FR: Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells. Eur J Biochem 189, 415-421 (1990)
79. B receptor mRNA is down-regulated by endothelin through decreasing the intracellular stability of mRNA molecules. Biochem Biophys Res Commun 186, 342-347 (1992)
80. B receptor mRNA: participation of cAMP. J Cardiovasc Pharmacol 26, Supp 3, 272-275 (1995)
81. B receptor subtype mRNA by angiotensin II in rat cardiomyocytes. Biochem Biophys Res Commun 194, 1282-1287 (1993)
82. B receptor. Biochem Biophys Res Commun 186, 355-362 (1992)
83. B mRNA expression in primary cultured astrocytes. Jpn J Pharmacol 67, Supp I, 243 (1995)
84. A receptor mRNA and increases responsiveness to endothelin-1 of rat aortic smooth muscle cells in primary culture. Biochem Biophys Res Commun 188, 719-726 (1992)
85. Nambi P, Pullen M, Wu HL, Nuthulaganti P, Elshourbagy N and Kumar C: Dexamethasone down-regulates the expression of endothelin receptors in vascular smooth muscle cells. J Biol Chem 267, 19555-19559 (1992)
86. Arai H, Nakao K, Takaya K, Hosoda K, Ogawa Y, Suga S, Nakanishi S and Imura H: The human endothelin-B receptor gene. J Biol Chem 268, 3463-3470 (1993)
87. Eguchi S, Hirata Y, Imai T, Kanno K and Marumo F: Phenotypic change of endothelin receptor subtype in cultured rat vascular smooth muscle cells. Endocrinology 134, 222-228 (1994)
88. Yamashita J, Yoshimasa T, Arai H, Hiraoka J, Takaya K, Miyamoto Y, Ogawa Y, Itoh H and Nakao K: Cis elements for transcriptional regulation of the human endothelin-A receptor gene. J Cardiovasc Pharmacol 26, Supp 3, 272-275 (1995)
89. Sokolovsky M: Endothelin receptor heterogeneity, G-proteins, and signaling via cAMP and cGMP cascades. Cell Mol Neurobiol 15, 561-571 (1995)
90. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T and Harris RC: Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest 83, 336-342 (1989)
91. Takuwa Y, Kasuya Y, Takuwa N, Kudo M, Yanagisawa M, Goto K, Masaki T and Yamashita K: Endothelin receptor is coupled to phospholipase C via a pertussis toxin insensitive guanine nucleotide binding regulatory protein in vascular smooth muscle cells. J Clin Invest 85, 653-658 (1990)
92. Simonson MS and Dunn MJ: Cellular signaling by peptides of the endothelin gene family. FASEB J 4, 2989-3000 (1990)
93. Silberberg SD, Poder TC and Lacerda A: Endothelin increases single channel calcium currents in coronary arterial smooth muscle cells. FEBS Lett 247, 68-72 (1989)
94. 2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA 86, 3915-3918 (1989)
95. Inoue Y, Oike M, Nakao K, Kitamura K and Kuriyama H: Endothelin augments unitary calcium channel currents on the smooth muscle cell membrane of guinea pig portal vein. J Physiol (Lond) 423, 171-191 (1990)
96. Kasuya Y, Takuwa Y, Yanagisawa M, Masaki T and Goto K: A pertussis toxin-sensitive mechanism of endothelin action in porcine coronary artery smooth muscle. Br J Pharmacol 107, 456-462 (1992)
97. Resink TJ, Scott-Burden T and Buhler FR: Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells. Eur J Biochem 189, 415-421 (1990)
98. Liu Y, Geisburhler B and Jones AW: Activation of multiple mechanisms including phopholipase D by endothelin-1 in rat aorta. Am J Physiol 262, C941-C946 (1992)
99. Griendling KK, Tsuda T and Alexander RW: Endothelin stimulates diacyglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells. J Biol Chem 264, 8237-8240 (1989)
100. + exchange activation by endothelin in vascular smooth muscle cells. Am J Hypertens 4, 776-779 (1991)
101. Chua BH, Krebs CJ, Chua CC and Diglio CA: Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 262, E412-E416 (1992)
102. Bogoyevitch MA, Glennon PE and Sugden PH: Endothelin 1, phorbol esters and phenylephirine stimulate MAP kinase activities in ventricular cardiomyocytes. FEBS Lett 317, 271-275 (1993)
103. Simonson MS, John JM and Dunn MJ: Differential regulation of fos and jun gene expression and AP 1 cis element activity by endothelin isopeptides. Possible implication for mitogenic signaling by endothelin. J Biol Chem 267, 8643-8649 (1992)
104. Simonson MS: Endothelins: multifunctional renal peptides. Physiol Rev 73, 375-411 (1993)
105. B. Am J Physiol 267, C1130-C1135 (1994)
106. Cazaubon S, Parker PJ, Strosberg AD and Couraud P-O: Endothlins stimulate tyrosine phosphorylation and activity of p42/mitogen-activated protein kinase in astrocytes. Biochem J 293, 381-386 (1993)
107. Wang Y, Simonson MS, Pouyssëgur J and Dunn MJ: Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells. Biochem J 287, 589-594 (1992)
108. Kasuya Y, Abe Y, Hama H, Sakurai T, Asada S, Masaki T and Goto K: Endothelin-1 activates mitogen-activated protein kinases through two independent signalling pathways in rat astrocytes. Biochem Biophys Res Commun 204, 1325-1333 (1994)
109. Cazaubon SM, Ramos-Morales F, Fischer S, Schweighoffer F, Strosberg AD and Couraud P-O: Endothelin induces tyrosine phosphorylation and GRB2 association of Shc in astrocytes. J Biol Chem 269, 24805-24809 (1994)
110. Herman WH and Simonson MS: Nuclear signaling by endothelin-1. J Biol Chem 270, 11654-11661 (1995)
111. Daub H, Weiss FU, Wallasch C and Ullrich A: Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557-560 (1996)
112. Takigawa M, Sakurai T, Kasuya Y, Abe Y, Masaki T and Goto K: Molecular characterization of guanine-nucleotide-binding regulatory proteins which couple to endothelin receptors. Eur J Biochem 228, 102-108 (1995)
113. A) antagonist isolated from Streptomyces misakiensis. Biochem Biophys Res Commun 178, 132-137 (1991)
114. A receptor. Life Sci 50, 247-255 (1992)
115. A selectivity. J Med Chem 35, 2139-2142 (1992)
116. B-mediated blood pressure responses in rats. J Pharmacol Exp Ther 270, 728-733 (1994)
117. Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, Kojo H, Notsu Y, Ono T and Nakanishi S: Subtype selectivity of a novel endothelin antagonist, FR 139317, for the two endothelin receptors in trasfected Chinese hamster ovary cells. Mol Pharmacol 43, 127-131 (1993)
118. A receptors. Br J Pharmacol 111, 4-6 (1994)
119. A receptor distribution. J Cardiovasc Pharmacol 22, Supp 8, S128-S131 (1993)
120. B receptor. Cardiovasc Drug Rev 11, 253-270 (1993)
121. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M and Yano M: Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonists, BQ-788. Proc Natl Acad Sci USA 91, 4892-4896 (1994)
122. B-selective antagonist IRL 2500 in conscious spontaneously hypertensive and Wistar-Kyoto rats. J Cardiovasc Pharmacol 26 Supp 3, S389-S392 (1995)
123. Doherty AM, Cody WL, He JX, De Pue PL, Leonard DM, Dunber JB Jr, Hill RE, Flynn MA and Reynolds EE: Design of C-terminal peptide antagonists of endothelin: structure-activity relationships of ET-1[16-21, D-His16]. Bioorg Med Chem Lett 3, 497-502 (1993)
124. Clozel M, Breu V, Burri K, Cassai JM, Fischli W, Gray GA, Hirth G, Loffler BM, Muller M, Neidhart W and Ramuz H: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365, 759-761 (1993)
125. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassai JM, Hirth G, Muller M, Neidhart W and Ramuz H: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin antagonist. J Pharmacol Exp Ther 270, 228-235 (1994)
126. Elliott JD, Lago MA, Cousins RD, Gao A, Leber JD, Erhard KF, Nambi P, Elshourbagy NA, Kumar C, Lee JA, Bean JW, DeBrosse CW, Eggleston DS, Brooks DP, Feuerstein G, Ruffolo RRJr, Weinstock J, Gleason JG, Peishoff CE and Ohlstein EH: 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J Med Chem 37, 1553-1557 (1994)
127. Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M and Lago A: SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 91, 8052-8056 (1994)
128. A receptor antagonist. J Pharmacol Exp Ther 273, 1410-1417 (1995)
129. Williams JrDL, Murphy KL, Nolan NA, O'Brien JA, Pettibone JA, Kivlighn SD, Krause SM, Lis EV, Zingara GJ, Gabel RA, Clayton FC, Siegl PKS, Zhang K, Naue J, Vyas K, Walsh TF, Fitch KJ, Chakravarty PK, Greenlee WJ and Clineschmidt VB: Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. J Pharmacol Exp Ther 275, 1518-1526 (1995)
130. Krause SM, Walsh TF, Greenlee WJ, Ranaei R and Kivlighn SD: Renal protection by endothelin antagonist, L-754,142, following aortic cross-clamping in the dog. Circulation 92, Supp 1, 1065 (1995)
131. Yamauchi R, Hoshino T, Ban Y, Kikkawa K, Murata S, Nawano M and Toriumi W: Effects of T-0115, a novel orally active endothelin antagonist, on monocrotaline-induced pulmonary hypertension in rats. Jap J Pharmacol 71, Supp I, 236P (1996)
132. Hoshino T, Yamauchi R, Ban Y, Kikkawa K and Murata S: Pharmacological profile of T-0115, a potent nonpeptide endothelin receptor antagonist. Jpn J Pharmacol 71, Supp I, 237P (1996)
133. Nagase T, Mase T, Niiyama K, Takahashi H, Naya A, Katsuki K, Fukami T, Hayama T, Noguchi K, Hisaka A, Ozaki S, Ihara M, Fukuroda T, Nishikibe M, Yano M and Ishikawa K: Cyclopentenopyridine derivatives: potent orally active and durable non-peptide endothelin A receptor antagonists. AFMC Internatl Med Chem Symp (Abstract), P5 M133 (1995)
134. A/B endothelin receptor-selective antagonists. J Cardiovasc Pharmacol 26, Supp 3, S358-S361 (1995)
135. Maguire JJ, Kuc RE, Doherty AM and Davenport AP: Potency of PD155080, an orally active ETA receptor antagonist, determined for human endothelin receptors. J Cardiovasc Pharmacol 26, Supp 3, S362-S364 (1995)
136. Haynes WG, Ferr CJ, O'Kane KPJ, Somerville D, Lomax CC and Webb DJ: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93, 1860-1870 (1996)
137. Vanhoutte PM: Is endothelin involved in the pathogenesis of hypertension? Hypertension 21, 747-758 (1993)
138. Otsuka A, Mikami H, Katahira K, Tsunetoshi T, Minamitani K and Ogihara T: Changes in plasma renin activity and aldosterone concentration in response to endothelin injection in dogs. Acta Endocrinol (Copenh) 121, 361-364 (1989)
139. Richard V, Hogie M, Clozel M, Loffler BM and Thuillez C: In vivo evidence of an endothelin-induced vasopressor tone after nitric oxide synthesis in rats. Circulation 91, 771-775 (1995)
140. Hirata Y, Takagi N, Fukuda Y and Marumo F: Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78, 225-228 (1989)
141. Battistini B, D'Orleans-Juste P and Sirois P: Biology of diseases, endothelin: Circulating plasma levels and presence in other biological fluids. Lab Invest 6, 600-628 (1993)
142. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol 114, 925-930 (1995)
143. Verma S, Bhanot S and Mcneill LH: Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 269, H2017-H2021 (1995)
144. Warner TD, Allcock GH and Vane JR: Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ123 and PD145065. Br J Pharmacol 112, 207-213 (1994)
145. Matsumura Y, Fujita K, Miyazaki Y, Takaoka M and Morimoto S: Involvement of endothelin-1 in deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy. J Cardiovasc Pharmacol 26, Supp 3, S456-S458 (1995)
146. Vemulapalli S, Watkins RW, Brown A, Cook J, Bernardino V and Chiu PJ: Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats. Life Sci 53, 783-793 (1993)
147. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K and Yano M: Antihypertensive effects of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci 52, 717-724 (1993)
148. A receptor antagonist. J Pharmacol Exp Ther 264, 1040-1046 (1993)
149. Ohlstein EH, Douglas SA, Ezekiel M and Gellai M: Antihypertensive effects of the endothelin antagonist BQ-123 in conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 22, Supp 8, S321-S324 (1993)
150. Donckier J, Stoleru L, Hayashida W, Van-Mechelen H, Selvais P, Galanti L, Clozel JP, Ketelslegers JM and Pouleur H: Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 92, 106-113 (1995)
151. Gardiner SM, March JE, Kemp PA, Mullins JJ and Bennett T: Haemodynamic effects of losartan and the endothelin antagonist, SB209670, in conscious, transgenic ((mRen-2) 27), hypertensive rats. Br J Pharmacol 116, 2237-2244 (1995)
152. Mullins JJ, Peters J and Ganten D: Fluminent hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344, 541-544 (1990)
153. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M and Harris P: The pathology of the early and late stages of primary-pulmonary hypertensin. Br Heart J 58, 204-213 (1987)
154. Cernacek P and Stewart DJ: Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 161, 562-567 (1989)
155. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matusmura M, Ueda T, Temma S, Shirakami G, Imura H and Mikawa H: Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects-evidence for increased production of endothelin in pulmonary circulation. Circulation 84, 2280-2285 (1991)
156. Cacoub P, Dorent R, Maistre G, Nataf P, Carayon A, Piette JC, Godeau P, Cabrol C and Gandjbakhch I: Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol 71, 448-450 (1993)
157. Ishikawa S, Miyauchi T, Ueno H, Ushinohama H, Sagawa K, Fukuzaki N, Sunagawa, Honda S, Sakai S, Yamaguchi I, Goto K and Sugishita Y: Influence of pulmonary blood pressure and flow on endothelin-1 production in humans. J Cardiovasc Pharmacol 26, 429-433 (1995)
158. Ishikawa S, Miyauchi T, Sakai S, Ushinohama H, Sagawa K, Fukazaki N, Kado H, Sunagawa H, Honda S, Ueno H, Yamaguchi I, Goto K and Sugishita Y: Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg 110, 271-273 (1995)
159. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Path FRC and Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328, 1732-1739 (1993)
160. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B and Hamid Q: Expression of endothelin-1 in lungs of patients with crystogenic fibbrosing alveolitis. Lancet 341, 1550-1554 (1993)
161. Stelzner TJ, O'Brien RF, Sato K, Webb S, Zamora MR, Sakurai T, Yanagisawa M, McMurtry IF and Fisher J: Increased endothelin-1 expression in rats with pulmonary hypertension. Am J Physiol 262, L614-L620 (1992)
162. Zamora MR, Stelzner TJ, Webb S, Panos RJ, Ruff LJ and Dempsey EC: Over-expression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cell from fawn-fooded rats. Am J Physiol 270, L101-L109 (1996)
163. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yanao M, Yamaguchi I, Sugishita Y and Goto K: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats wtih monocrotaline-induced pulmonary hypertension. Circ Res 73, 887-897 (1993)
164. Cassis LA, Rippetoe PA, Soltis EE, Painter DJ, Fitz R and Gillespie MN: Angiotensin II and monocrotaline-induced pulmonary hypertension: Effect of losartan (DuP753), a nonpeptide angiotensin type I receptor antagonist. J Pharmacol Exp Ther 262, 1168-1172 (1992)
165. Okada M, Yamashila C, Okada M and Okada K: Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation 92, 114-119 (1995)
166. Eddahibi S, Raffenstin B, Clozel M, Levame M and Adnot S: Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 268, H828-H835 (1995)
167. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K and Sugishita Y: Pulmonary hypertension caused by congestive heart failure is markedly ameliorated by chronic application of an endothelin receptor antagonist: increased expression of endothelin-1 mRNA and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J Am Coll Cardiol (in press)
168. Uchida Y, Ninomiya H, Saotome M, Nomura A, Ohtsuka M, Yanagisawa M, Goto K, Masaki T and Hasegawa S: Endothelin, a novel vasoconstrictor peptide, as potent bronchoconstrictor. Eur J Pharmacol 154, 227-228 (1988)
169. Hay DW, Henry PJ and Goldie RG: endothelin and the respiratory system. Trends Pharmacol Sci 14, 29-32 (1993)
170. Nomura A, Uchida Y, Kameyama M, Saotome M, Oki K and Hasegawa S: Endothelin and bronchial asthma. Lancet 2, 747-748 (1989)
171. Mattoli S, Soloperto M, Marini M and Fasoli A: Levels of endothelin in the bronchoalveolar lavage fluid of patients with symptomatic asthma and reversible airflow obstruction. J Allergy Clin Immunol 88, 376-384 (1991)
172. Vittori E, Marini M, Faaoki A, De Franchis R and Mattori S: Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids. Am Rev Respir Dis 146, 1320-1325 (1992)
173. Brezis M and Epstein FH: Cellular mechanisms of acute ischemic injury in the kidney. Annu Rev Med 44, 27-37 (1993)
174. Nord EP: Renal actions of endothelin. Kidney Int 44, 451-463 (1993)
175. Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda K, Ando M, Schichiri Y, Hirata Y and Marumo F: Plasma endothelin levels in patients with acute renal failure. N Engl J Med 321, 1127 (1989)
176. Shibouta Y, Suzuki N, Shino A, Matsumoto H, Terashita Z-I, Kondo K and Nishikawa K: Pathophysiological role of endothelin in acute renal failure. Life Sci 46, 1611-1618 (1990)
177. Nambi P, Pullen M, Jugus M and Gellai M: Rat kidney endothelin receptors in ischemia-induced acute renal failure. J Pharmacol Exp Ther 264, 345-348 (1993)
178. Kon V, Yoshioka T, Fogo A and Ichikawa I: Glomerular actions of endothelin in vivo. J Clin Invest 83, 1762-1767 (1989)
179. Lopez-Farre A, Gomez-Garre D, Bernabeu F and Lopez-Novoa M: A role for endothelin in the maintenance of post-ischemic renal failure in the rat. J Physiol (Lond) 444, 513-522 (1991)
180. Vemulapalli S, Chiu PJS, Chintala M and Bernardino V: Attenuation of ischemic acute renal failure by phosphoramidon in rats. Pharmacology 47, 188-190 (1993)
181. Mino N, Kobayashi M, Nakajima A, Amano H, Shimamoto K, Ishikawa K, Watanabe K, Nishikibe M, Yano Mand Ikemoto F: Protective effect of a selective endothelin receptor antagonist, BQ-123, in ishemic acute renal failure in rats. Eur J Pharmacol 221, 77-83 (1992)
182. A receptor antagonist in the rat. J Clin Invest 93, 900-906 (1994)
183. Benigni A, Zola C, Corna D, Orisio S, Longaretti L, Bertani T and Remuzzi G: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44, 440-444 (1993)
184. Gellai M, Jugus M, Fletcher T, Nambi P, Ohlstein ET, Elliott JD and Brooks DP: Nonpeptide endothelin receptor antagonists V: Prevention and reversal of acute renal failure in rat by SB 209670. J Pharmacol Exp Ther 275, 200-206 (1995)
185. Kopp J and Klotmann PE: Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1, 162-170 (1990)
186. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I and Hoover RL: Role of endothelin in cyclosporin induced glomerular dysfunction. Kidney Int 37, 1487-1491 (1990)
187. Kon V and Badr KF: Biological actions and pathophysiological significance of endothelin in the kidney. Kidney Int 40, 1-12 (1991)
188. Kon V and Awazu M: Endothelin and cyclosporin nephrotoxicity. Ren Fail 14, 345-350 (1992)
189. Perico N, Dadan J and Remuzzi G: Endothelin mediates the renal vasoconstriction induced by cyclosporin in the rat. J Am Soc Nephrol 1, 76-83 (1990)
190. Awazu M, Sugiura M, Inagami T, Ichikawa I and Kon V: Cyclosporin promotes glomerular endothelin binding in vivo. J Am Soc Nephrol 1, 1253-1258 (1990)
191. Brooks DP, Ohlstein EH, Contino LC, Storer B, Pullen M, Caltabiano M and Nambi P: Effect of nifedipine on cyclosporin A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. Eur J Pharmacol 194, 115-117 (1991)
192. Fogo F, Hellings SE, Inagami T and Kon V: Endothelin receptor antagonism is protective in in vivo acute cyclosporin toxicity. Kidney Int 42, 770-774 (1992)
193. Bloom ITM, Bertley FR and Garrison RN: Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery 114, 480-488 (1993)
194. Bunchman TE and Brookshire CA: Cyclosporin-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 88, 310-314 (1991)
195. Takahashi K, Totsune K and Mouri T: Endothelin in chronic renal failure. Nephron 66, 373-379 (1994)
196. Hama H, Kasuya Y, Sakurai T, Yamada G, Suzuki N, Masaki T and Goto K: Role of Endothelin-1 in astrocyte responses after acute brain damage. J Neurosci Res (in press)
197. Yamada G, Hama H, Kasuya Y, Masaki T and Goto K: Possible sources of endothelin-1 in damaged rat brain. J Cardiovasc Pharmacol 26, Supp 3, S486-S490 (1995)
198. Uesugi M, Kasuya Y, Hama H, Yamamoto M, Hayashi K, Masaki T and Goto K: Endogenous endothelin-1 initiates astrocytic growth after spinal cord injury. Brain Res 728, 255-259 (1996)
199. Ma KC, Nie XJ, Hoog A, Olsson and Zhang WW: Reactive astroctes in viral infections of the human brain express endothelin-like immunoreactivity. J Neurol Sci 126, 184-192 (1994)
200. Zhang WW, Badonic T, Hoog A, Jiang MH, Ma KC, Nie XJ and Olsson Y: Astrocytes in Alzheimer's disease express immunoreactivity to the vasoconstrictor endothelin-1. J Neurol Sci 122, 90-96 (1994)
201. Findlay JM, Weir BKA, Kanamaru K and Epinosal F: Arterial wall changes in cerebral vasospasm. Neurosurgery 25, 736-746 (1989)
202. Asano T, Ikegaki I, Suzuki S and Shibuya M: Endothelin and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun 159, 1345-1351 (1989)
203. Mima T, Yanagisawa M, Shigeno T, Saito A, Goto K, Takakura K and Masaki T: Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 20, 1553-1556 (1989)
204. Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F and Hirakawa K: Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet ii, 1402 (1990)
205. Fujimori A, Yanagisawa M, Saito A, Goto K, Masaki T, Mima T, Takakura K and Shigeno T: Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid hemorrhage. Lancet 336, 633 (1990)
206. Suzuki H, Sato S, Suzuki Y, Oka M, Tsuchiya T, Iino I, Yamanaka T, Ishihara N and Shimoda S: Endothelin immunoreactivity in cerebrospinal fluid of patients with subarachnoid haemorrhage. Ann Med 22, 233-236 (1990)
207. Kraus GE, Bucholz RD, Yook KW, Kneupfer MM and Smith KR: Cerebrospinal fluid endothelin-1 and endothelin-3 levels in normal and neurosurgical patients: a clinical study and literature review. Surg Neurol 35, 20-29 (1991)
208. Shigeno T, Mima Y, Yanagisawa M, Saito A, Goto K, Yamashita K, Takenouchi T, Matura N, Yamasaki Y, Yamada K, Masaki T and Takakura K: Prevention of cerebral vasospasma by actinomysin D. J Neurosurg 74, 940-943 (1991)
209. A receptor mRNA expression in a canine subrachnoid hemorrhage model. J Neurosurg 81, 759-764 (1994)
210. Alabadi JA, Salom JB, Torregross G, Miranda FJ, Jover T and Alborch E: Changes in the cerebrovascular effects of endothelin-1 and nicardipine after experimental subarachnoid hemorrhage. Neurosurgery 33, 707-715 (1993)
211. A receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci 49, 1869-1874 (1993)
212. Matsumura Y, Ikegawa R, Suzuki Y, Takaoka M, Uchida T, Kido H, Shinyama H, Hayashi K, Watanabe M and Morimoto S: Phosphoramidon prevents cerebral vasospasm following subarachinoid hemorrhage in dogs: The relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci 49, 841-848 (1991)
213. Hirose H, Ide K, Sakaki T, Takahashi R, Kobayashi M, Ikemoto F, Yano M and Nishikibe M: The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur J Pharmacol 277, 77-87 (1995)
214. Willette RN, Zhang H, Mitchell MP, Sauermelch CF, Ohlstein EH and Sulpizio AC: Nonpeptide endothelin antagonist: Cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke 25, 2450-2456 (1994)
215. Shigeno T, Clozel M, Sakai S, Saito A and Goto K: The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 37, 87-91 (1995)
216. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K and Masaki T: Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 2, 53-54 (1989)
217. B receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 114, 949-954 (1995)
218. Herbst C, Tippler B, Shams H and Simmet T: A role for endothelin in bicuculline-induced neurogenic pulmonary oedema in rats. Br J Pharmacol 115, 753-760 (1995)
219. Masuda E, Kawano S, Nagano K, Tsuji S, Takei Y, Hayashi N, Tsujii M, Oshita M, Michida T, Kobayashi I, Peng HB, Fusamoto H and Kamada T: Role of endogenous endothelin in pathogenesis of ethanol induced gastric mucosal injury in rats. Am J Physiol 265, G474-G481 (1993)
220. Whittle BJR: Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol 110, 3-17 (1993)
221. Chua BH, Krebs CJ, Chua CC and Diglio CA: Endothelin stimulates protein synthesis in smooth muscle cells. Am J Physiol 262, E412-E416 (1992)
222. Douglas SA, Louden C, Vickery-Clark LM, Storer BL and Hart T: A role for endogenous endothelin-1 in neointimal formation following rat carotid artery balloon angioplasty: protective effects of the non-peptide endothelin receptor antagonist SB 269670. Circ Res 75, 190-197 (1994)
223. Pribnow D, Muldoon LL, Fajado M, Theodor L, Chen LY and Magun BE: Endothelin induces transcription of fos/jun family genes: a prominent role for calcium ion. Mol Endocrinol 6, 1003-1012 (1992)
224. Janakidevi K, Fisher MA, Del Vecchio PJ, Tiruppathi C, Figge J, Malik AB: Endothelin 1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle. Am J Physiol 263, C1295-C1301 (1992)
225. Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T and Marumo F: Endothelin-1 is an autocrine-paracrine growth factor for human cancer cell lines. J Clin Invest 87, 1867-1871 (1991)
226. Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K and Masaki T: A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J Biol Chem 264, 7856-7861 (1989)
227. Jahan H, Kobayashi S, Nishimura J and Kanaide H: Endothelin-1 and angiotensin II act as progression but not competence growth factors in vascular smooth muscle cells. Eur J Pharmacol 295, 261-269 (1996)
228. Hahn AW, Resink TJ, Bernhardt J, Ferracin F and Buhler FR: Stimulation of autocrine platelet derived growth factor-AA homodimer and transforming growth factor in vascular smooth muscle cells by vasoconstrictive peptides. Biochem Biophys Res Commun 178, 1451-1456 (1991)
229. Kusuhara M, Yamaguchi K, Ohnishi A, Abe K, Kimura S, Oono H, Hori S and Nakamura Y: Endothelin potentiates growth factor-stimulated DNA synthesis in Swiss 3T3 cells. Jpn J Cancer Res 80, 302-305 (1989)
230. Weissberg PL, Witchell C, Davenport AP, Hesketh TR and Metcalfe JC: The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis 85, 257-262 (1990)
231. Weber H, Webb ML, Serafino R, Taylor DS, Moreland S, Norman J and Molloy CJ: Endothelin-1 and angiotensin 11 stimulate delayed mitogenesis in cultured rat aortic smooth muscle cells: evidence for common signalling mechanisms. Mol Endocrinol 8, 148-158 (1994)
232. Hahn AW, Resink TJ, Kern F and Buhler FR: Peptide vasoconstrictors, vessel structure, and vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 22, Supp 5, S37-S43 (1993)
233. Douglas SA, Vickery-Clark LM, Storer BL, Hart T, Louden C, Elliott JD and Ohlstein EH: A role for endogenous endothelin-1 in neointimal formation following rat carotid artery balloon angioplasty: protective effects of the non-peptide endothelin receptor antagonist SB209670. Circ Res 75, 190-195 (1994)
234. Wang X, Douglas SA, Louden C, Vickery-Clark LM, Feuerstein GZ and Ohlstein EH: Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 78, 322-328 (1996)
235. Yu JCM and Devenport AP: Secretion of endothelin-1 and endothelin-3 by human cultured vascular smooth muscle cells. Br J Pharmacol 114, 551-557 (1995)
236. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM and Burnett JC Jr: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325, 997-1001 (1991)
237. Martin-Nizard F, Houssaini HS, Lestavel-Delattre S, Duriez P and Fruchart JC: Modified low density lipoproteins activate human macrophages to secrete immunoreactive endothelin. FEBS Lett 293, 127-130 (1991)
238. Boulanger CM, Tanner FC, Beau ML, Han AWA, Warner A and Lüscher TF: Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 70, 1191-1197 (1992)
239. 125I-endothelin-1 accumulation in experimental arterial injury. Eur J Nucl Med 20, 1141-1145 (1993)
240. 125I-Endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: a possible role for endothelin in intimal hyperplasia and atherosclerosis. J Cardiovasc Pharmacol 22, Supp 8, 343-347 (1993)
241. Daschwood MR, Allen SP, Luu TN and Muddle JR: The effect of the ETA receptor antagonist, FR139317, on 125I-ET-1 binding to the atherosclerotic human coronary artery. Br J Pharmacol 112, 386-389 (1994)
242. Thompson EEW, Marino TA, Uboh CE, Kent RL and Cooper C: Atrophy reversal and cardiocyte redifferentiation in reloaded cat myocardium. Circ Res 54, 367-377 (1984)
243. Carter WJ, Van Der Weijden Benjamin WS and Faas FH: Effect of thyroid hormone on protein turnover in cultured cardiac myosytes. J Mol Cell Cardiol 17, 897-905 (1985)
244. Zimmer HG: Correlation between haemodynamic and metabolic changes in models of experimental cardiac hypertrophy. Eur Heart J 5, 171-179 (1984)
245. 1-adrenergic receptor interaction: evidence for independent regulation of growth and beating. Circ Res 56, 844-894 (1985)
246. Baker KM, Chernin MI, Wixson SK and Aceto JF: Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259, H324-H332 (1990)
247. Maughan D, Low E, Litten R, Brayden J and Alpert N: Calcium-activated muscle from hypertrophied rabbit hearts. Mechanical and correlated biochemical changes. Circ Res 44, 279-287 (1979)
248. Scheuer J and Bahn AK: Cardiac contractile proteins. Adenosine triphosphatase activity and physiological function. Circ Res 45, 1-12 (1979)
249. Morkin E: Stimulation of cardiac myosin adenosine triphosphatase in thyrotoxicosis. Circ Res 44, 1-7 (1979)
250. Hoh JFY, Mcgrath PA and Hal PT: Electrophoretic analysis of multiple forms of rat cardiac myosin. Effect of hypophysectomy and thyroxine replacement. J Mol Cell Cardiol 10, 1053-1076 (1978)
251. Mercadier JJ, Lompre AM, Wisnewsky C, Samuel JL, Bercovici J, Swynghedauw B and Schwartz K: Myosin isoenzymic changes in several models of rat cardiac hypertrophy. Circ Res 49, 525-532 (1981)
252. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG and Weber KT: Fibrillar collagen and myocardial stiffness in the intact hypertrophied left ventricle. Circ Res 64, 1041-1050 (1989)
253. Weber KT, Jalil JE, Janicki JS and Pick R: Myocardial collagen remodeling in pressure overload hypertrophy: a case for interstitial heart disease. Am J Hypertens 2, 931-940 (1989)
254. Chapman DK, Weber KT and Eghbali M: Regulation of fibrillar collagen type I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 67, 787-794 (1990)
255. Ignotz RA and Massague J: Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261, 4337-4345 (1986)
256. Pentinen RP, Kobayashi K and Bornstein P: Transforming growth factor-β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA 85, 1105-1108 (1988)
257. Eghbali M, Tomek R, Sukhatme VP, Woods C and Bhambi B: Differential effects of transforming growth factor-β1 and phorbol myristate acetate on cardiac fibroblast: regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 69, 483-490 (1991)
258. 1, fibronectin, and collagen. Am J Physiol 262, H1861-H1866 (1992)
259. Starksen NF, Simpson PC, Bishopric N, Coughlin SR, Lee WMF, Escobedo JA and Williams LT: Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proc Natl Acad Sci USA 83, 8348-8350 (1986)
260. Komura I, Kurabayashi M, Takaku F and Yazaki Y: Expression of cellular oncogenes in the myocardium during the developmental stage and pressure-overload hypertrophy of the rat heart. Circ Res 62, 1075-1079 (1988)
261. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y and Goto K: Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett 332, 31-34 (1993)
262. Arai M, Yoguchi A, Iso T, Takahashi T, Imai S, Murata K and Suzuki T: Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 268, H2084-H2091 (1995)
263. Nishida M, Springhorn JP, Kelly RA and Smith TW: Cell-cell signaling between adult rat ventricular myocytes and cardiac microvascular endothelial cells in heterotypic primary culture. J Clin Invest 91, 1934-1941 (1993)
264. De Keulenaer GW, Andries LJ, Sys SU and Brutsaert DL: Endothelin-mediated positive inotropic effect induced by reactive oxygen species in isolated cardiac muscle. Circ Res 76, 878-884 (1995)
265. Ho H, Hirata Y, Adachi S, Tanaka M, Koike A, Noguchi A, Marumo F and Hiroe M: Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardioyocytes. J Clin Invest 92, 398-403 (1993)
266. Yamazaki T, Kudo S, Zou Y, Shojima I and Komuro I: Endothelin-1 and angiotensin II synergistically mediate stretch-induced cardiac hypertrophy. Circulation 90, Supp 1, 1-569 (1995)
267. 1 expression in rat ventricular myocytes. J Clin Invest 94, 1470-1476 (1994)
268. Torre-Amione G, Kapadia S, Lee J, Durand J-B, Bies RD, Young JB and Mann DL: Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 93, 704-711 (1996)
269. A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89, 2198-2203 (1994)
270. Ho KK, Pinsky JL, Kannel WB and Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88, 107-115 (1993)
271. Pfeffer MA: Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 46, 455-466 (1995)
272. Kannel WB, Sorlie P and MacNamara: Prognosis after initial myocardial infarction: Framingham study. Am J Cardiol 44, 503-512 (1979)
273. Cody RJ, Haas GJ, Binkley PF, Capers Q and Kelley R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85, 504-509 (1992)
274. Cacoub P, Dorent R, Nataf P, Carayon A, Maistre G, Piette JC, Godeau P, Cabrol C and Gandjbakhch I: Plasma endothelin and pulmonary pressures in patients with congestive heart failure. Am Heart J 126, 1484-1488 (1993)
275. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R and Bertel O: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346, 732-736 (1995)
276. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K and Sugishita Y: Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: Marked increase in endothelin-1 production in the failing heart. Circulation 93, 1214-1222 (1996)
277. Tonnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M and Christensen G: Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res 76, 767-772 (1995)
278. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K and Sugishita Y: Remarkable improvement in long-term mortality and prevention of unfavorable ventricular remodeling by inhibition of the upregulated myocardial endothelin pathway in rats with chronic heart failure. Nature 384, 353-355 (1996)
279. Omland T, Lie RT, Aakvaag A, Arsland T and Dickstein K: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89, 1573-1579 (1994)
280. Stawski G, Olsen UB and Grande P: Cytotoxic effect of endothelin-1 during 'stimulated' ishaemia in cultured myocytes. Eur J Pharmacol 201, 123-124 (1991)
281. Prasad MR: Endothelin stimulates degradation of phospholipids in isolated rat heart. Biochem Biophys Res Commun 174, 952-957 (1991)
282. Shubetai HE, McDonough PM, Harris AN, Knowlton KU, Glemboski CC, Brown JH and Chien KR: Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 265, 20555-20562 (1990)
283. Guarda E, Katwal LC, Myeres PR, Tyagi SC and Weber KT: Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27, 2130-2134 (1993)
284. Guarda E, Myeres PR, Brilla CG, Tyagi SC and Weber KT: Endothelial cell induced modulation of cardiac fibroblast collagen metabolism. Cardiovasc Res 27, 1004-1008 (1993)
285. Cody RJ, Haas GJ, Binkley PF, Capers Q and Kelly R: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85, 504-509 (1992)